Primary biliary cholangitis (PBC) can result in life-altering cholestatic pruritus and fatigue, but treatment options are limited. Seladelpar, a peroxisome proliferator-activated receptor-delta (PPARδ) agonist, has demonstrated potent anti-cholestatic effects in clinical studies. This open-label, uncontrolled phase 2 study in PBC patients evaluated the effects of 1-year of seladelpar treatment on measures of pruritus and quality of life.

中文翻译：

---

Seladelpar 改善了原发性胆汁性胆管炎患者的瘙痒、睡眠和疲劳测量并降低了血清胆汁酸

原发性胆汁性胆管炎 (PBC) 可导致改变生活的胆汁淤积性瘙痒和疲劳，但治疗选择有限。Seladelpar 是一种过氧化物酶体增殖物激活受体-δ (PPARδ) 激动剂，已在临床研究中显示出有效的抗胆汁淤积作用。这项针对 PBC 患者的开放标签、非对照 2 期研究评估了 1 年的 seladelpar 治疗对瘙痒和生活质量测量的影响。